Which Tyrosine Kinase Inhibitor Must We Apply Before? A Case Report of Crizotinib-resistant Patient with Concomitant EGFR and EML4-ALK Gene Mutations
Küçük Resim Yok
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Univ West Indies Faculty Medical Sciences
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
The concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocations in lung adenocancers are very rare scenarios. Until now, 42 cases described in the literature have all been treated by different drugs. There is no overall consensus regarding the treatment for this adenocarcinoma subgroup. We report here a case of lung adenocarcinoma with concomitant EGFR mutation in exon 21 (L858R) and ALK rear-rangement in primary tumour, EGFR mutation in exon 21 (L858R) and no ALK rearrangement in its synchronous metastasis. We treated this patient with crizotinib as the second-line therapy (after the first line docetaxel-cisplatin chemotherapy), but no response was obtained. The therapeutic choice for the lung adenocancer patients with concomitant EGFR mutation and ALK rearrangement is unclear. Examination of c-ros oncogene 1 mutation can be used as an indicator in the prediction of the crizotinib treatment success. The ALK mutation may not responsible for the resistance to EGFR-tyrosine kinase inhibitors (TKI), and EGFR-TKI can be initiated to EGFR and ALK dual mutant patients as the first treatment.
Açıklama
Anahtar Kelimeler
Adenocancer, anaplastic lymphoma kinase, crizotinib, lung epidermal growth factor receptor mutation, Cell Lung-Cancer, Factor Receptor Mutation, Alk Rearrangement, Fusion Gene, Adenocarcinoma, Gefitinib, Responsiveness, Translocation
Kaynak
West Indian Medical Journal
WoS Q Değeri
Q4
Scopus Q Değeri
Q4
Cilt
69
Sayı
3
